Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

4 Jan 2022

Leuven, BELGIUM, Boston, MA, US – January 4, 2022 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, today announces its management will present and meet with investors at the H.C. Wainwright BioConnect 2022 Virtual Conference:

H.C. Wainwright BioConnect 2022 Virtual Conference

January 10-13, 2022

Pre-recorded CEO Presentation available starting on January 10 at 7:00 AM ET

For more information, please visit Oxurion's events page

Press release attachment: 
Tags: 
Event; Investors